Table 1.
Characteristics of the BenchMark XT platform protocol.
Fig 1.
PD-L1 staining pattern using PD-L1 IHC 22C3 pharmDx and the 22C3 antibody–based LDT on the BenchMark XT platform.
(A, B) Analytic PD-L1–positive slide from Agilent. (C–F) PD-L1 staining pattern in human tonsil tissue. (E, F) Dynamic range of the germinal center macrophages (light-brown colored, IHC score +1) and the intense staining of the invaginated epithelium (dark-brown colored, IHC score +3) in serial samples. LDT, laboratory-developed test; PD-L1, programmed death ligand 1.
Fig 2.
Correlation of PD-L1 CPS as a continuous variable between the 22C3 antibody–based LDT on the BenchMark XT or the BenchMark ULTRA platform and PD-L1 IHC 22C3 pharmDx for the following samples: (A) CC (n = 77), (B) ESCC (n = 80), (C) HNSCC (n = 126), (D) TNBC using the BenchMark XT platform (n = 118), (E) TNBC using the BenchMark ULTRA platform (n = 30), and (F) UC (n = 121).
CC, cervical cancer; CPS, combined positive score; ESCC, esophageal squamous cell carcinoma; HNSCC, head and neck squamous cell carcinoma; ICC, intraclass correlation coefficient; IHC, immunohistochemistry; LDT, laboratory-developed test; PD-L1, programmed death ligand 1; TNBC, triple-negative breast cancer; UC, urothelial carcinoma.
Table 2.
Clinical interpretation of PD-L1 status using the 22C3 antibody–based LDT on the BenchMark XT or BenchMark ULTRA platform and PD-L1 IHC 22C3 pharmDx.
Fig 3.
Pan-tumor (N = 522) correlation of PD-L1 CPS as a continuous variable between the 22C3 antibody–based LDT on the BenchMark XT platform and PD-L1 IHC 22C3 pharmDx.
CPS, combined positive score; ICC, intraclass correlation coefficient; IHC, immunohistochemistry; LDT, laboratory-developed test; PD-L1, programmed death ligand 1.
Fig 4.
PD-L1 staining pattern using PD-L1 IHC 22C3 pharmDx and the 22C3 antibody–based LDT on the BenchMark XT platform in CC, ESCC, HNSCC, TNBC, and UC.
CC, cervical cancer; ESCC, esophageal squamous cell carcinoma; HNSCC, head and neck squamous cell carcinoma; LDT, laboratory-developed test; PD-L1, programmed death ligand 1; TNBC, triple-negative breast cancer; UC, urothelial carcinoma.